AR065928A1 - Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo - Google Patents

Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo

Info

Publication number
AR065928A1
AR065928A1 ARP080101384A ARP080101384A AR065928A1 AR 065928 A1 AR065928 A1 AR 065928A1 AR P080101384 A ARP080101384 A AR P080101384A AR P080101384 A ARP080101384 A AR P080101384A AR 065928 A1 AR065928 A1 AR 065928A1
Authority
AR
Argentina
Prior art keywords
intensity
docetaxel
peak
anhydrous crystalline
crystalline form
Prior art date
Application number
ARP080101384A
Other languages
English (en)
Inventor
Namdu Kim
Woo Seob Shin
Chang Young Kil
Seung Hwan Cho
Jaehyuk Jung
Gi Jeong Kim
Eun Jung Lim
Youngho Moon
Gwan Sun Lee
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AR065928A1 publication Critical patent/AR065928A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

La presente provee un docetaxel cristalino anhidro estable que tiene actividad antitumoral y antileucémica, y un método para la preparacion del mismo. Reivindicacion 1: Una forma cristalina anhidra de docetaxel caracterizada porque es de formula (1), en donde, Ph es fenilo; Ac es acetilo; Bz es benzoilo; y Boc es t-butoxicarbonilo. Reivindicacion 3: La forma cristalina anhidra de docetaxel de la reivindicacion 1, caracterizada porque su espectro de difraccion de rayos X muestra picos mayores que tienen una intensidad de pico relativa (100xI/II0; I: la intensidad del pico, I0: la intensidad del pico máximo) de al menos 100% a valores 2 theta de 4,88; 9,22; 9,72; 10,38; 11,30; 11,88; 13,34; 14,56; 15,14; 16,62; 17,28; 17,66; 19,02; 19,62; 19,86; 20,86; 21,86; 24,58; y 26,98. Reivindicacion 4: La forma cristalina anhidra de docetaxel de la reivindicacion 1, caracterizada porque su espectro de difraccion de rayos X muestra picos mayores que tienen una intensidad de pico relativa (100xI/I0 I: la intensidad del pico, I0: la intensidad del pico máximo) de al menos 55 % a valores 2theta de 4,62; 8,22; 9,20; 10;64; 11,44; 12,42; 13,80; 14,20; 15,28; 17,28; 18,46; 20,62; y 21,86. Reivindicacion 5: La forma cristalina anhidra de docetaxel de la reivindicacion 1, caracterizada porque su espectro de difraccion de rayos X muestra picos mayores que tienen una intensidad de pico relativa (100xI/I0; I: la intensidad del pico, l0: la intensidad del pico máximo) de al menos 50 % a valores 2theta de 4,06; 4,82; 7,58; 8,20; 9,84; 11,44; 12,76; 13,62; 14,16; 16,98; 19,18; 19,60; y 19,90.
ARP080101384A 2007-04-10 2008-04-03 Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo AR065928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070035065A KR100878455B1 (ko) 2007-04-10 2007-04-10 안정한 무수결정형 도세탁셀 및 이의 제조방법

Publications (1)

Publication Number Publication Date
AR065928A1 true AR065928A1 (es) 2009-07-08

Family

ID=39831157

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101384A AR065928A1 (es) 2007-04-10 2008-04-03 Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo

Country Status (10)

Country Link
US (1) US20100099897A1 (es)
EP (1) EP2155709A4 (es)
JP (1) JP2010523647A (es)
KR (1) KR100878455B1 (es)
CN (1) CN101652356A (es)
AR (1) AR065928A1 (es)
CL (1) CL2008000980A1 (es)
PE (1) PE20090045A1 (es)
TW (1) TW200906813A (es)
WO (1) WO2008123751A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
KR101149600B1 (ko) * 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
EP2542613A4 (en) 2010-03-01 2013-12-11 Univ British Columbia DERIVATED HYPER BRANCHED POLYGLYCEROLS
BR112012028037A2 (pt) 2010-05-03 2016-08-02 Teikoku Pharma Usa Inc formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JP2018527287A (ja) 2015-05-15 2018-09-20 アルブヴェックス エルエルシー ドセタキセルおよびヒト血清アルブミンの複合体
US11419842B2 (en) 2016-10-27 2022-08-23 Zhuhai Beihai Biotech Co., Ltd. Neutral pH compositions of Docetaxel and human serum albumin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
WO2003087078A1 (en) * 2002-04-05 2003-10-23 Natural Pharmaceuticals, Inc. Selective acylation of secondary hydroxyl groups
US6838569B2 (en) * 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
ES2325506T3 (es) * 2003-12-12 2009-09-07 Quiral Quimica Do Brasil Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones.
FR2864340B1 (fr) * 2003-12-19 2006-03-24 Commissariat Energie Atomique Microcomposant comportant une microcavite hermetique et procede de fabrication d'un tel microcomposant
CN100420681C (zh) 2005-04-29 2008-09-24 上海奥锐特国际贸易有限公司 多烯紫杉醇三水物的制备方法
BRPI0606132A2 (pt) * 2005-10-12 2009-06-02 Sicor Inc formas cristalinas de docetaxel e processos para seu preparo
KR100995390B1 (ko) * 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
NZ576355A (en) * 2006-10-20 2012-04-27 Scinopharm Singapore Pte Ltd Process for making crystalline anhydrous docetaxel

Also Published As

Publication number Publication date
WO2008123751A1 (en) 2008-10-16
TW200906813A (en) 2009-02-16
EP2155709A4 (en) 2010-09-15
CN101652356A (zh) 2010-02-17
KR100878455B1 (ko) 2009-01-13
JP2010523647A (ja) 2010-07-15
CL2008000980A1 (es) 2008-08-22
KR20080091945A (ko) 2008-10-15
US20100099897A1 (en) 2010-04-22
EP2155709A1 (en) 2010-02-24
PE20090045A1 (es) 2009-03-22

Similar Documents

Publication Publication Date Title
AR065928A1 (es) Docetaxel cristalino anhidro estable y metodo para la preparacion del mismo
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CY1122919T1 (el) Διεγερτες sgc
MY176680A (en) Cyclic amides as metap-2 inhibitors
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
AR096759A1 (es) Formas sólidas de un inhibidor de quinasa macrocíclica
BR112012018780A2 (pt) "pneu com modelo de banda de rodagem para redução de ruído"
CY1119269T1 (el) Θεραπεια βλαβων που προκαλουνται απο ιους
CY1117752T1 (el) Τετρακυκλικη ενωση
GT200600280A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
HK1166788A1 (es)
EA200901250A1 (ru) Сульфониламидные производные для лечения аномального роста клеток
MX2015007584A (es) Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
PH12014501639A1 (en) Pharmaceutical compositions and methods
IN2014CN03432A (es)
DK2252322T3 (da) Vaccinesammensætninger
EA201401062A1 (ru) Бициклические пиразиноновые производные
PH12016501034A1 (en) Oral care compositions and methods
TR201910685T4 (tr) Bir inaktive RGD bölgesine sahip modifiye osteopontin peptitleri ve bunların kullanımları.
TR201902057T4 (tr) Tetrasiklin bileşikleri.
CY1116542T1 (el) Νεα παραγωγα (συμπυκνωμενης ετεροκυκλο-πιπεριδινης)-(πιπεραζινυλ)-1-αλκανονης ή (συμπυκνωμενης ετεροκυκλο-πυρρολιδινης)-(πιπεραζινυλ)-1-αλκανονης, και χρηση αυτων ως αναστολεων p75
UA101961C2 (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form
MX358871B (es) Composiciones y metodos para el cuidado oral.
MX344134B (es) Rotores formados utilizando curvas envolventes.
CR20120561A (es) Composiciones y métodos para el diagnóstico y tratamiento de tumores

Legal Events

Date Code Title Description
FA Abandonment or withdrawal